about
Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma.Molecular genetics of peripheral T-cell lymphomas.Update on the pharmacotherapy for myelodysplastic syndromes.Brentuximab vedotin for treatment of systemic T-cell lymphoma.Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications.Recent advances in intestinal lymphomas.Therapeutic Options for Aggressive T-Cell Lymphomas.How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan.Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.CD30-positive malignant lymphomas: time for a change of management?Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas.
P2860
Q30240160-3FBBF6CC-7042-47A0-918B-494B038C237DQ33598637-1D0BC079-B161-4B43-8B1F-9BA2E27E55DCQ38183757-C2038A47-2614-47F7-9ECF-97E3AD9AEDE1Q38235662-2A050FC7-FD75-4F12-B038-5F640E031074Q38247076-FA74A1EF-86B6-4B0A-8644-C738C3E6660EQ38289038-F4D218C2-AAF4-4C25-A02D-3721F15DD485Q38339462-42F49A82-B4E5-4F96-B840-DE480E2AFDA9Q38675843-30919898-8A79-4DC3-9B6F-A69D1FD24CE5Q38782072-0E8D4758-9589-4A23-9E0D-68CE8C878C71Q38896683-1C74A685-53F7-4C47-B988-9242784A3C6FQ39284101-E8D6FF9D-D3A3-4921-BA2A-78AF914181BFQ40791381-A6A537DC-8240-4279-9F6F-1839FC9FEDBEQ42923845-1535BF92-B621-4B85-BDFF-4CD055C9CC2DQ43065863-83D8EA62-0628-4EC9-804E-EB4E36F00F4DQ46523865-101272B7-7FD1-49A4-82C9-CA6E728163C4Q48157671-1EC26888-F1A6-4F57-83A5-915FF5DF8699Q52337767-A1B799C9-0AFF-4022-A45F-E3AF8AEE126C
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
CD30 expression in peripheral T-cell lymphomas.
@en
CD30 expression in peripheral T-cell lymphomas.
@nl
type
label
CD30 expression in peripheral T-cell lymphomas.
@en
CD30 expression in peripheral T-cell lymphomas.
@nl
prefLabel
CD30 expression in peripheral T-cell lymphomas.
@en
CD30 expression in peripheral T-cell lymphomas.
@nl
P2093
P2860
P1433
P1476
CD30 expression in peripheral T-cell lymphomas.
@en
P2093
Carlo Sagramoso Sacchetti
Claudio Agostinelli
Elena Sabattini
Marco Pizzi
Pamela Baldin
Stefano A Pileri
Valentina Tabanelli
P2860
P356
10.3324/HAEMATOL.2013.084913
P577
2013-05-28T00:00:00Z